Atjaunināt sīkdatņu piekrišanu

Access to Experimental Drugs in Terminal Illness: Ethical Issues [Mīkstie vāki]

(Univ Of The Witwatersrand)
  • Formāts: Paperback / softback, 244 pages, weight: 386 g
  • Izdošanas datums: 29-Aug-2000
  • Izdevniecība: Haworth Press Inc
  • ISBN-10: 0789005646
  • ISBN-13: 9780789005649
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 46,04 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 244 pages, weight: 386 g
  • Izdošanas datums: 29-Aug-2000
  • Izdevniecība: Haworth Press Inc
  • ISBN-10: 0789005646
  • ISBN-13: 9780789005649
Citas grāmatas par šo tēmu:
Access to Experimental Drugs in Terminal Illness: Ethical Issues helps you understand the ethical dilemmas experienced by those suffering from terminal illnesses who are denied legal access to experimental, potentially life-saving drugs and who are then pressured into clinical tests designed to test and further the approval of those very same drugs. You'll get a better understanding of the urgent need for an ethical and legal re-evaluation of the current drug approval and drug testing process in most western countries.

Access to Experimental Drugs in Terminal Illness assists you in gaining a better understanding of the changes to the drug testing and drug approval process political AIDS activism has achieved. In many ways, AIDS is a paradigmatic case for how people with terminal illnesses can make a difference to drug testing and drug approval. Specifically, you'll read about the importance of respecting the autonomy of terminally ill people who request to be given access to experimental drugs. The author gathers support for this view from a wide range of classical and contemporary moral philosophers. He also discusses the practical implications of his ethical analysis of the current regulations for drug approval and drug testing.

Overall, you'll see that Access to Experimental Drugs in Terminal Illness is an innovative contribution to the current debate raging over the ethical justifiability of current clinical trials and their design. You'll find that your understanding of this debate will flourish and increase as you realize the need for improvement in the drug approval process worldwide.
Preface ix Introduction 1(8) Autonomy---Access to Experimental Drugs and the Terminally III 9(80) Immanuel Kant 15(9) Weak Paternalism 24(17) John Stuart Mill Weak Paternalism 41(15) Joel Feinberg Weak Paternalism 56(8) Gerald Dworkin Weak Paternalism 64(10) Tom L. Beauchamp James F. Childress Ruth R. Faden Strong Paternalism 74(7) Robert Young The Importance of Respecting Individual Autonomy 81(4) Summary of the Philosophical Debate 85(2) Practical Implications of the Arguments 87(2) Should We Restrict Access to Experimental Drugs to Promote Clinical Trials? 89(56) Research Clinical Trials---Are They Designed to Help Current or Future Patients? 97(4) Physicians and Patients 101(6) The Fischl/Richman AZT Trial 107(14) Ethical Analysis of the Fischl/Richman AZT Trial 121(12) Coercive Offers, or You Cannot Have It Both Ways 133(5) Placebos and Other Drugs 138(2) Summary 140(5) Costs and Other Practical Problems 145(24) Access to Experimental Drugs in Societies with Universal Health Care 151(5) Access to Experimental Drugs in Societies Without Universal Health Care 156(5) Provision of Information About Experimental Drugs 161(6) Practical Cultural Hindrances in Exercising Autonomy 167(2) Conclusion 169(4) Notes 173(32) Bibliography 205(14) Index 219